Department of Health and Human Services
National Institutes of Health
Toggle navigation
Search
Home
About the Clinical Center
Clinical Trials & You
Participate in a Study
Referring a Patient
How to Search
Contact Us
Search the Studies
Browse by Institute
Searched Result
469 Studies found from all possible combinations of your search terms. Select a protocol that you wish to review.
Protocol Number
Title
Protocol Status
Min-Max Age
Institute
Keywords
001961-C
A Molecularly Driven Phase 1b Dose Escalation and Dose Expansion Study of the DNA-PK Inhibitor Peposertib (M3814) in Combination with the ATR Inhibitor M1774
Participants currently recruited/enrolled
18-120 Years
NCI
001951-C
Natural History Study of Kaposi Sarcoma
Recruitment has not started
18-120 Years
NCI
001886-C
A Phase 1 Study of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers
Participants currently recruited/enrolled
18-120 Years
NCI
001859-C
A Phase I Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
Recruitment has not started
18-120 Years
NCI
001808-C
MAIN-CAV: Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab after First-Line Platinum-Based Chemotherapy in Patients with Metastatic Urothelial Cancer
Participants currently recruited/enrolled
18-120 Years
NCI
001784-C
Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation
Recruitment has not started
18-120 Years
NCI
001778-C
A Randomized, Open Label, Two-Arm, Multicenter Phase 2 Study to Evaluate Efficacy and Safety of PRGN-2009 in Combination with Pembrolizumab Versus Pembrolizumab in Patients with Recurrent or Metastatic Cervical Cancer
Recruitment has not started
18-120 Years
NCI
001776-C
A Phase 1 Dose Escalation and Expansion Study of GIGA-564, a Minimally Blocking Anti-CTLA-4 Monoclonal Antibody, in Participants with Locally Advanced or Metastatic Solid Tumor Malignancies
Participants currently recruited/enrolled
18-120 Years
NCI
001771-C
EAY191-S3, Phase II Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants With AKT-Altered Advanced Non-Breast Solid Tumors (A ComboMATCH Treatment Trial)
Participants currently recruited/enrolled
18-100 Years
NCI
001770-C
Molecular Analysis for Combination Therapy Choice (ComboMATCH) EAY191-N4: A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients With Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers
Participants currently recruited/enrolled
18-120 Years
NCI
001756-C
A Phase 1 Study of Peposertib (M3814) and Low-Dose Liposomal Doxorubicin in Patients with Metastatic Leiomyosarcoma and Other Soft Tissue Sarcomas
Participants currently recruited/enrolled
18-120 Years
NCI
001749-C
ComboMATCH Treatment Trial E4: Nilotinib and Paclitaxel in Patients with Prior Taxane-Treated Solid Tumors
Participants currently recruited/enrolled
18-120 Years
NCI
001733-C
A Phase 1 Clinical Trial of CA-4948 in Combination with Gemcitabine and Nab-Paclitaxel in Metastatic or Unresectable Pancreatic Ductal Carcinoma
Participants currently recruited/enrolled
18-100 Years
NCI
001732-C
A Phase 1 Study of the Polymerase Theta (POL-Theta) Inhibitor Novobiocin in BRCA-mutant and Other DNA Damage Repair-Deficient Solid Tumors
Participants currently recruited/enrolled
18-120 Years
NCI
001730-C
Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination with Immunotherapy Vaccine PRGN-2009 in Subjects with Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer
Recruitment has not started
18-120 Years
NCI
001715-C
A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, formerly PT2977) Monotherapy in Participants with Advanced Pheochromocytoma/Paraganglioma (PPGL) or Pancreatic Neuroendocrine Tumor (pNET), von Hippel-Lindau (VHL) Disease-Associ
Recruitment has not started
12-120 Years
NCI
001713-C
A Phase II Trial of Surface Electrical Stimulation for Urinary Incontinence in Men Treated for Prostate Cancer
Participants currently recruited/enrolled
18-120 Years
NCI
001704-C
Randomized Phase 2 Study of Cabozantinib, Ipilimumab, and Nivolumab in Patients with Soft Tissue Sarcoma
Clinical hold/Recruitment or enrollment suspended
18-100 Years
NCI
001696-C
Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST)
Recruitment has not started
3-120 Years
NCI
001695-C
A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SNS-101 (anti-VISTA) as Monotherapy and in Combination with Cemiplimab in Patients with Advanced Solid Tumors
Recruitment has not started
18-120 Years
NCI
001665-C
Molecular Analysis for Combination Therapy Choice (ComboMATCH)
Participants currently recruited/enrolled
2-120 Years
NCI
001662-C
A Phase Ib Clinical Trial to Evaluate the Administration of Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction with a Vaccine Directed Against these Antigens in Participants with Metastatic Cance
Participants currently recruited/enrolled
18-72 Years
NCI
001657-C
Phase 1 Umbrella Trial of Erlotinib In Combination with Select Tyrosine Kinase Inhibitors In Adult Patients with Advanced Solid Tumors
Recruitment has not started
18-120 Years
NCI
001620-C
Pilot Prospective Study for PET-CT Imaging in Participants with Relapsed/Refractory Acute Leukemias
Participants currently recruited/enrolled
5-39 Years
NCI
001600-C
Phase 2 Study Evaluating the Functional Status of the Adrenal Glands with [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism
Recruitment has not started
18-120 Years
NCI
001599-C
Phase I/II Trial of Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL)
Recruitment has not started
18-120 Years
NCI
001591-C
Pilot Study of CBX-12 Pharmacodynamics in Patients with Advanced Solid Tumors
Recruitment has not started
18-100 Years
NCI
001590-C
Rapid Analysis and Response Evaluation of Combination Anti-neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 3 Tiragolumab + Atezolizumab
Participants currently recruited/enrolled
18-100 Years
NCI
001583-C
A Phase 1/2 Open-Label, Multicenter, Dose Escalation and Expansion Study of AVB-001, an Intraperitoneally Administered, Cell-Generated, Human IL-2 Immunotherapy in Patients With Platinum-Resistant, High-Grade, Serous Adenocarcinoma of the Ovary, Primary
Completed Study; data analyses ongoing
18-120 Years
NCI
001582-C
Phase I/Ib Study Evaluating Safety and Efficacy of PRGN-3005 (Autologous CAR T Cells) in Advanced Stage Platinum Resistant Ovarian Cancer Patients
Recruitment has not started
18-120 Years
NCI
001578-C
A Phase 1/2 Study of Tiragolumab (NSC# 827799, IND# 161266) and Atezolizumab (NSC# 783608, IND# 161266) in Patients with Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
Participants currently recruited/enrolled
3-100 Years
NCI
001572-C
A Phase II Study of Bevacizumab in Adults with Recurrent Respiratory Papillomatosis (RRP)
Participants currently recruited/enrolled
18-120 Years
NCI
001569-C
A Phase I Study to Investigate the Safety of the Ubiquitin Activating Enzyme Inhibitor TAK-243 in Adult Solid Tumor and Lymphoma Patients
Recruitment has not started
18-100 Years
NCI
001567-C
Observational Study of Rates of Prostate Cancer Diagnosis in Men of African Ancestry Using MRI and MRI Guided Biopsy
Participants currently recruited/enrolled
35-120 Years
NCI
001564-C
A Phase II Sequential Window of Opportunity Trial of Pembrolizumab + N-803 alone or in Combination with PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma
Recruitment has not started
18-120 Years
NCI
001563-C
Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)
Participants currently recruited/enrolled
18-120 Years
NCI
001559-C
A Feasibility Multicenter Phase I Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
Recruitment has not started
18-120 Years
NCI
001557-C
Phase I/II Trial of Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination with HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants with Advanced or Metastatic Endometrial Cancer (EC)
Recruitment has not started
18-120 Years
NCI
001556-C
Phase II Trial of Enzalutamide and M9241 in PET Positive Recurrent Prostate Cancer (pprPC) without Testosterone Lowering Therapy
Participants currently recruited/enrolled
18-120 Years
NCI
001554-C
Phase I/II Trial of Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older with Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
Recruitment has not started
12-120 Years
NCI
001552-C
Phase II Study of Enasidenib in IDH2-mutated Malignant Sinonasal and Skull Base Tumors
Participants currently recruited/enrolled
18-120 Years
NCI
001549-C
Phase II Evaluation of Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent in Subjects with BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma
Participants currently recruited/enrolled
18-120 Years
NCI
001548-C
A Phase I/II Study of CDX-1140, a CD40 Agonist, in Combination with Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects with Biliary Tract Carcinoma (BTC)
Participants currently recruited/enrolled
0-120 Years
NCI
001547-C
A First-in-Human Phase I Trial with Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas
Participants currently recruited/enrolled
18-120 Years
NCI
001545-C
A Phase Ib/II Multicenter Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS
Recruitment has not started
18-120 Years
NCI
001544-C
Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG with Entinostat and Nivolumab as Adjuvant Therapy following Chemoradiation Therapy with or without Surgery for Locally Advanced Esophageal Cancer
Participants currently recruited/enrolled
18-120 Years
NCI
001542-C
Phase Ib Study of Imatinib to Increase RUNX1 Activity in Participants with Germline RUNX1 Deficiency
Participants currently recruited/enrolled
18-120 Years
NCI
001541-C
A Phase I/II Trial of Eltanexor (KPT-8602) with Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes
Participants currently recruited/enrolled
18-120 Years
NCI
001538-C
A Phase II Study of Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma and Multicentric Castleman Disease
Participants currently recruited/enrolled
18-120 Years
NCI
001537-C
Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)
Recruitment has not started
18-120 Years
NCI
001536-C
Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 with Pembrolizumab before Standard Treatment in Subjects with Newly Diagnosed HPV-Associated Oropharyngeal Cancer
Participants currently recruited/enrolled
18-120 Years
NCI
001535-C
A Phase II Study of Sacituzumab Govitecan with or without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) such as Small Cell, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile Cancer
Recruitment has not started
18-120 Years
NCI
001534-C
Phase I/II Trial of PLX038 in Primary Central Nervous System Tumors containing MYC or MYCN Amplifications
Participants currently recruited/enrolled
18-120 Years
NCI
001533-C
A Phase II Multicenter Study of Enfortumab Vedotin with or without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)
Recruitment has not started
18-120 Years
NCI
001531-C
A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplantation with JSP191-Based Conditioning in Participants with GATA2 Deficiency
Participants currently recruited/enrolled
6-70 Years
NCI
001525-C
A Phase II Trial Evaluating 18F-Fluciclovine PET/CT in Multiple Myeloma
Participants currently recruited/enrolled
18-120 Years
NCI
001524-C
A Phase I Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T- Cells for Treating B-cell Malignancies
Participants currently recruited/enrolled
18-75 Years
NCI
001523-C
A Phase II Study of Lurbinectedin with or without Avelumab in Small Cell Carcinoma of the Bladder (LASER)
Participants currently recruited/enrolled
18-120 Years
NCI
001516-C
Phase I Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-Small Cell Lung Cancer
Participants currently recruited/enrolled
18-120 Years
NCI
001109-C
Defining the Natural History of Squamous Cell Carcinoma in Fanconi Anemia
Participants currently recruited/enrolled
8-125 Years
NCI
001099-C
A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-Fusion Molecule, in Subjects with Unresectable, Locally Advanced, or Metastatic Solid Tumors that
Participants currently recruited/enrolled
18-125 Years
NCI
001092-C
Exploring the Role of Palliative Care in Phase 1 Enrolled Pediatric Oncology Patients
Enrolling by Invitation
18-125 Years
NCI
001056-C
Longitudinal Early Advance Care Planning Discussions and Documentation (LEADD) Program: An Exploratory Study in Adolescents and Young Adults (AYAs) Receiving Hematopoietic Stem Cell Transplant
Participants currently recruited/enrolled
18-120 Years
NCI
001004-C
A Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination with Gemcitabine in Adult Subjects with Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon Oncosignature(R) Status
Participants currently recruited/enrolled
18-120 Years
NCI
000975-C
Collection of Blood, Bone Marrow, Skin, Saliva, and Stool Samples from Healthy Volunteers Used for Comparative Analysis of Myeloid Malignancies
Participants currently recruited/enrolled
18-125 Years
NCI
000958-C
Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenvironment
Enrolling by Invitation
18-125 Years
NCI
000954-C
A Phase 1/2 Single Arm Open-Label Clinical Trial of TC-510 In Patients with Advanced Mesothelin-Expressing Cancer
No longer recruiting/follow-up only
18-120 Years
NCI
000930-C
A Phase 1b/2 Study of HCW9218, a Bifunctional TGF-beta Antagonist/IL-15 Protein Complex, for Advanced Pancreatic Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
000860-C
A Phase I/II Study of Zotiraciclib for Recurrent High-Grade Gliomas with Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations
Participants currently recruited/enrolled
18-125 Years
NCI
000826-C
An Open Label, Randomized, Phase 2 Study to Evaluate the Safety and Efficacy of MTL-CEBPA Administered in Combination with Sorafenib or Sorafenib Alone, in TKI Na(SqrRoot) ve Participants with Previously Treated Advanced Hepatocellular Carcinoma (HCC) an
Recruitment has not started
18-125 Years
NCI
000792-C
A Pilot Trial to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following CAR T-cell Induced Remission in Pediatric Patients with B Lineage Acute Lymphoblastic Leukemia
Participants currently recruited/enrolled
1-25 Years
NCI
000783-C
Phase I/Ib trial evaluating the safety and efficacy of BET inhibitor, ZEN003694 with PD-1 inhibitor, nivolumab with or without CTLA-4 inhibitor, ipilumumab in solid tumors
Participants currently recruited/enrolled
18-125 Years
NCI
000732-C
A Long-Term Follow-Up Study of Patients Who Received VOR33
Participants currently recruited/enrolled
18-125 Years
NCI
000731-C
A First-In-Human, Open-Label, Multicenter Study of VOR33 in Patients with Acute Myeloid Leukemia who are at High-Risk for Leukemia Relapse following Hematopoietic Cell Transplantation
Participants currently recruited/enrolled
18-70 Years
NCI
000726-C
A Randomized Phase 2 Study of Atezolizumab with or without Selinexor in Alveolar Soft Part Sarcoma (AXIOM)
Participants currently recruited/enrolled
18-125 Years
NCI
000696-C
A Phase III, Multicenter, International Study with a Parallel, Randomized, Double-blind, Placebo-controlled, 2 Arm Design to Assess the Efficacy and Safety of Selumetinib in Adult Participants with NF1 who have Symptomatic, Inoperable Plexiform Neurofibr
No longer recruiting/follow-up only
18-120 Years
NCI
000692-C
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 2 Talazoparib and Temozolomide
Participants currently recruited/enrolled
12-125 Years
NCI
000678-C
Rare Tumors and Cancer Predisposition in Individuals and Families
Participants currently recruited/enrolled
0-125 Years
NCI
000666-C
A Phase I/II Study of Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)
Participants currently recruited/enrolled
18-100 Years
NCI
000661-C
Comprehensive Molecular and Clinical Evaluation of Pediatric and Adult Myelodysplastic Syndromes (MDS)
Participants currently recruited/enrolled
0-120 Years
NCI
000657-C
Acceptance and Commitment Therapy for Caregivers of Children with a RASopathy: An Internal Pilot Feasibility Study and Follow-up Phase III Randomized Controlled Trial
Participants currently recruited/enrolled
18-125 Years
NCI
000647-C
An Open-label, Multicenter Follow-up Study to Collect Long-term Data on Participants from Multiple Bintrafusp alfa (M7824) Clinical Studies
Recruitment has not started
18-120 Years
NCI
000643-C
Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Participants currently recruited/enrolled
18-125 Years
NCI
000633-C
Phase 1/2 Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies
Participants currently recruited/enrolled
18-125 Years
NCI
000631-C
Investigation of the Cognitive Aftereffects of Neurotoxicity in Children and Young Adults with Relapsed/Refractory Hematologic Malignancies who Receive CAR T-cell Therapy
Clinical hold/Recruitment or enrollment suspended
5-125 Years
NCI
000628-C
A Study of Prospective Monitoring of Subjects with Biochemically Recurrent Prostate Cancer Using 18F-DCFPyL
Participants currently recruited/enrolled
18-125 Years
NCI
000613-C
Phase I/II Trial to Determine the Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination with Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis after Reduced Intensity Conditioning and Peripheral Blood St
Participants currently recruited/enrolled
12-125 Years
NCI
000612-C
Phase 1 Study of NT-I7 (rhIL-7-hyFc) for the Treatment of Kaposi Sarcoma in Patients With or Without Infection with HIV
No longer recruiting/follow-up only
18-125 Years
NCI
000611-C
A Phase II Trial of Focal Ultrahypofractionated Stereotactic Radiation Therapy for the Treatment of Unifocal Prostate Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
000596-C
Phase II Study of Olaparib in Subjects with Advanced Pancreatic Acinar Cell Carcinoma
Participants currently recruited/enrolled
18-125 Years
NCI
000580-C
A Phase 1/2, Open Label Dose-Escalation and Expansion Trial of Nkt2152, an Orally Administered Hif2(alpha) Inhibitor, to Investigate Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity in Patients with Advanced Clear Cell Renal Cell Carcinom
Participants currently recruited/enrolled
18-125 Years
NCI
000569-C
Clinical Study of Bioactivity of Low Dose Apalutamide in Prostate Cancer Patients Scheduled for Prostatectomy
Participants currently recruited/enrolled
18-125 Years
NCI
000520-C
Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG with or without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
000516-C
Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma involving the Central Nervous System
No longer recruiting/follow-up only
18-125 Years
NCI
000509-C
An Open Label, Multi-Center Roll-Over Study to Assess Long-Term Safety in Patients Who are Ongoing or Have Completed a Prior Global Novartis or GSK Sponsored Tafinlar (Dabrafenib) and/or Mekinist (Trametinib) Study and are Judged by the Investigator to B
Enrolling by Invitation
18-125 Years
NCI
000491-C
Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)
Participants currently recruited/enrolled
18-125 Years
NCI
000489-C
Phase I/II Study Using Prophylactic Donor Lymphocyte Infusion Early Post-Transplant After Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for High-Risk Hematologic Malignancies
Participants currently recruited/enrolled
12-120 Years
NCI
000484-C
Randomized Phase II Trial of Durvalumab (D) plus Olaparib (O) and Cediranib (C: DOC) Compared to OC or DC or Chemotherapy in Platinum-Resistant Recurrent Ovarian Cancer with Prior Bevacizumab
No longer recruiting/follow-up only
18-125 Years
NCI
000481-C
Phase II Trial of 18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy
Participants currently recruited/enrolled
18-125 Years
NCI
000478-C
A Phase I/II Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Bone Marrow Transplantation Followed by GVHD Prophylaxis with Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies in People Living with HIV (PLWH)
Clinical hold/Recruitment or enrollment suspended
12-120 Years
NCI
000475-C
Phase 2 Study of Rogaratinib (BAY 1163877) in the Treatment of Patients with Sarcoma Harboring Alterations in Fibroblast Growth Factor Receptor (FGFR) 1-4 and SDH-deficient Gastrointestinal Stromal Tumor (GIST)
Participants currently recruited/enrolled
18-125 Years
NCI
000473-C
A Randomized Phase II Study of Systemic Chemotherapy with or without HAI FUDR-Dexamethasone in Patients with Unresectable Intrahepatic Cholangiocarcinoma
Participants currently recruited/enrolled
18-125 Years
NCI
000462-C
Phase 2, Open-label, Single-arm, Window of Opportunity Study of ASP-1929 Photoimmunotherapy with Fluorescence Imaging in Patients With Operable Primary or Recurrent Head and Neck or Cutaneous Squamous Cell Carcinoma
Participants currently recruited/enrolled
18-125 Years
NCI
000423-C
Feasibility and Preliminary Efficacy of Acceptance and Commitment Therapy (ACT) for Sleep Disturbances in Adults with Sickle Cell Disease (SCD): A Pilot Randomized Controlled Trial
Participants currently recruited/enrolled
18-55 Years
NCI
000404-C
A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects with VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) Syndrome
Participants currently recruited/enrolled
18-75 Years
NCI
000359-C
Phase I/II study to reduce post-transplantation cyclophosphamide dosing for older or unfit patients undergoing bone marrow transplantation for hematologic malignancies
Participants currently recruited/enrolled
12-85 Years
NCI
000356-C
A Phase I/II Trial of BMS-986253 in Myelodysplastic Syndromes
Completed Study; data analyses ongoing
18-125 Years
NCI
000354-C
Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
Participants currently recruited/enrolled
18-125 Years
NCI
000337-C
Natural History Study of KSHV-Associated Multicentric Castleman's Disease
Participants currently recruited/enrolled
18-125 Years
NCI
000328-C
Bicalutamide Implants (Biolen ) with Radiation Therapy in Patients with Localized Prostate Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
000324-C
Phase 1/2 Dose Escalation Study of CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults with Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
Participants currently recruited/enrolled
3-35 Years
NCI
000317-C
A Phase II, Open-Label Trial of PT-112 in Subjects with Thymoma and Thymic Carcinoma
Participants currently recruited/enrolled
18-125 Years
NCI
000307-C
Phase II Study Evaluating the Efficacy of M9241 in Combination with Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects with Metastatic Colorectal Cancer or Intrahepatic Cholangiocarcinoma
Participants currently recruited/enrolled
18-125 Years
NCI
000305-C
Exploratory Phase II Study of LAnreotide in Unresectable or Metastatic Pheochromocytoma / PARAganglioma
No longer recruiting/follow-up only
18-125 Years
NCI
000303-C
A Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide Vs. Temozolomide and Olaparib For Advanced Pheochromocytoma And Paraganglioma
Participants currently recruited/enrolled
18-125 Years
NCI
000302-C
A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies
Participants currently recruited/enrolled
18-125 Years
NCI
000293-C
Managing Cancer and Living Meaningfully (CALM) Therapy in Individuals Diagnosed with a Primary Central Nervous System Tumor
Clinical hold/Recruitment or enrollment suspended
18-125 Years
NCI
000277-C
Imaging and Biopsy of People with HIV-1 Undergoing Analytic Treatment Interruption
Participants currently recruited/enrolled
18-125 Years
NCI
000274-C
Phase I Trial of Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
Participants currently recruited/enrolled
18-125 Years
NCI
000264-C
A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response
Participants currently recruited/enrolled
18-120 Years
NCI
000254-C
A Phase II Trial of the Superenhancer Inhibitor Minnelide in Advanced Refractory Adenosquamous Carcinoma of the Pancreas (ASCP)
Participants currently recruited/enrolled
18-125 Years
NCI
000251-C
The Effect of Diet and Exercise on ImmuNotherapy and the Microbiome (EDEN)
Participants currently recruited/enrolled
18-120 Years
NCI
000237-C
Phase II Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis from Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
000194-C
A Phase I Trial of ProAgio, an anti- alpha-v-beta3 Integrin Cytotoxin, for Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies
Participants currently recruited/enrolled
18-120 Years
NCI
000193-C
Phase 1 Study of Copanlisib with Dose-adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and other High-Grade B-cell Lymphomas
Completed Study; data analyses ongoing
18-125 Years
NCI
000178-C
Hyperspectral Analysis of Sweat Metabolite Biometrics for Real-Time Detection of COVID-19
Participants currently recruited/enrolled
18-120 Years
NCI
000176-C
A Phase I/II Trial of Lurbinectedin with Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High Grade Neuroendocrine Cancers
Participants currently recruited/enrolled
18-125 Years
NCI
000144-C
A Phase I/II Study of Sacituzumab Govitecan plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors
Participants currently recruited/enrolled
18-125 Years
NCI
000115-C
A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants with Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants with Solid Tumors on PD1/PDL1 Inhibitor Therapy, Including Booster D
Completed Study; data analyses ongoing
18-125 Years
NCI
000114-C
A Phase II Study Evaluating T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination with the Immunocytokine M9241 in Localized High and Intermediate Risk Prostate Cancer Treated with Androgen Deprivation Therapy
Participants currently recruited/enrolled
18-125 Years
NCI
000103-C
A Randomized Study Investigating the Pharmacokinetics of Standard Interval Dosing Compared to Extended Interval Dosing of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers
Participants currently recruited/enrolled
18-125 Years
NCI
000096-C
A Phase II study of Immunotherapy Combination: Irradiated PD-L1 CAR-NK cells plus Pembrolizumab plus N-803 for Subjects with Recurrent/Metastatic Gastric or Head and Neck Cancer
Participants currently recruited/enrolled
18-120 Years
NCI
000092-C
Phase 1/2 study of Vincristine and Temozolomide in Combination with PEN-866 for Adolescents and Young Adults with Relapsed or Refractory Solid Tumors
Recruitment has not started
12-39 Years
NCI
000085-C
Assessing Sleep and Circadian Rhythms in Primary Brain Tumors Patients: An Observational Study
Enrolling by Invitation
18-99 Years
NCI
000081-C
A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Chondrosarcoma and Clear Cell Sarcoma
Completed Study; data analyses ongoing
2-125 Years
NCI
000080-C
18F-DCFPyL PET/CT in Hepatocellular Carcinoma
Participants currently recruited/enrolled
18-125 Years
NCI
000067-C
Understanding the Patient Experience: Symptom Burden in Pediatric Patients Receiving Chimeric Antigen Receptor (CAR) T-cell Therapy
Completed Study; data analyses ongoing
2-125 Years
NCI
000059-C
Phase I Study of Intratumor Injection of anti-Mesothelin Immunotoxin LMB-100 with Ipilimumab in Malignant Mesothelioma
Completed Study; data analyses ongoing
18-120 Years
NCI
000048-C
A Multi-Center Natural History Study of Precision-Based Genomics in Prostate Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
000045-C
A Phase I Trial of T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and other KK-LC-1 Positive Epithelial Cancers
Participants currently recruited/enrolled
18-120 Years
NCI
000030-C
Phase 2 Study of Bintrafusp alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON).
No longer recruiting/follow-up only
18-125 Years
NCI
22-C-0005
Phase I Dose Escalation and Expansion Study of Tazemetostat in Combination with Topotecan and Pembrolizumab in Recurrent Small Cell Lung Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
22-C-0004
A Phase II Study of Bevacizumab, Erlotinib and Atezolizumab in Subjects with Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Associated or Sporadic Papillary Renal Cell Cancer
Participants currently recruited/enrolled
12-120 Years
NCI
22-C-0003
Feasibility of Evaluating Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral Microdialysis
Participants currently recruited/enrolled
18-39 Years
NCI
21-C-0032
GD2-CAR PERSIST: Production and Engineering of GD2-Targeted, Receptor Modified T Cells (GD2CART) for Osteosarcoma or Neuroblastoma to Increase Systemic Tumor Exposure
Participants currently recruited/enrolled
0-40 Years
NCI
21-C-0030
Phase I Study of GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Hepatocellular Carcinoma (HCC)
Participants currently recruited/enrolled
18-125 Years
NCI
21-C-0026
A Phase I/II Study of Abemaciclib in Patients with HIV-associated and HIV-negative Kaposi Sarcoma
Participants currently recruited/enrolled
18-125 Years
NCI
21-C-0024
A Phase 2 Adaptive Study of Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients with High-Risk Smoldering Multiple Myeloma
Participants currently recruited/enrolled
18-125 Years
NCI
21-C-0023
A Phase I Study of Pomalidomide and Nivolumab in Patients with Virus-Associated Malignancies with or without HIV
Participants currently recruited/enrolled
18-125 Years
NCI
21-C-0022
A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR(TM) T Cells in Subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
Participants currently recruited/enrolled
10-75 Years
NCI
21-C-0021
SARC037: A Phase I Study to Evaluate the Safety of Trabectedin Administered as a 1-Hour Infusion in Ewing Sarcoma Patients in Combination with Low Dose Irinotecan and 3'Deoxy-3'-18F Fluorothymidine (18F-FLT) Imaging
No longer recruiting/follow-up only
6-125 Years
NCI
21-C-0019
Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients with Relapsed/Refractory Hairy Cell Leukemia and Variant
Participants currently recruited/enrolled
18-125 Years
NCI
21-C-0017
Magnetic Resonance Image (MRI) Guided High Energy Ultrasound for Focal Prostate Cancer Ablation
Participants currently recruited/enrolled
18-125 Years
NCI
21-C-0015
Phase II Trial Evaluating the Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment with Immune Checkpoint Inhibition (ICI) in Patients with Newly Diagnosed Glioblastoma or Gliosarcoma
Participants currently recruited/enrolled
18-125 Years
NCI
21-C-0014
Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination with Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
Participants currently recruited/enrolled
18-120 Years
NCI
21-C-0013
A Phase I/II Study of Adjuvant PRGN-2012 in Adult Patients with Recurrent Respiratory Papillomatosis
Participants currently recruited/enrolled
18-120 Years
NCI
21-C-0012
Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis from Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies
Participants currently recruited/enrolled
18-125 Years
NCI
21-C-0011
A Phase 0/I/II Study of the Cyclin-Dependent Kinase(CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type 1 (NF1) Related Atypical Neurofibromas
Participants currently recruited/enrolled
12-125 Years
NCI
21-C-0009
A Natural History Study of Children and Adults with Olfactory Neuroblastoma
Participants currently recruited/enrolled
3-120 Years
NCI
21-C-0007
A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers
Participants currently recruited/enrolled
18-120 Years
NCI
21-C-0006
Phase II Study Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers
Participants currently recruited/enrolled
18-125 Years
NCI
21-C-0001
A Phase I/II Study of M9241 with Docetaxel and Abiraterone in Adults with Metastatic Castration Sensitive and M9241 with Docetaxel in Castration Resistant Prostate Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
20-C-0167
Close Assessment and Testing for Chronic Graft-vs-Host Disease (CATCH Study)
Participants currently recruited/enrolled
18-125 Years
NCI
20-C-0164
Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
20-C-0162
A Phase 1 Study of Venetoclax with Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies
No longer recruiting/follow-up only
18-125 Years
NCI
20-C-0161
Prospective Study of Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis
Participants currently recruited/enrolled
6-125 Years
NCI
20-C-0155
Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination with BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) with CV301 TRICOM in Advanced Solid Tumors (STAT)
Completed Study; data analyses ongoing
18-120 Years
NCI
20-C-0154
Pilot Study of DS-8201a Pharmacodynamics in Patients with HER2-expressing Advanced Solid Tumors
Participants currently recruited/enrolled
18-120 Years
NCI
20-C-0150
Phase II Randomized Trial of Bethesda Protocol Compared to Cambridge Method for Detection of Early Stage Gastric Cancer in CDH1 Mutation Carriers
Participants currently recruited/enrolled
18-125 Years
NCI
20-C-0149
Phase II Trial of Olaparib (LYNPARZA) plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas that Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors
Participants currently recruited/enrolled
18-125 Years
NCI
20-C-0142
A Phase II Study of Bintrafusp alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects with Urothelial Carcinoma
Completed Study; data analyses ongoing
18-125 Years
NCI
20-C-0138
Phase II Trial of Combination Immunotherapy in Subjects with Advanced Small Bowel and Colorectal Cancers
No longer recruiting/follow-up only
18-120 Years
NCI
20-C-0130
A Feasibility Study Investigating the Use of Machine Learning to Analyze Facial Imaging, Voice and Spoken Language for the Capture and Classification of Cancer/Tumor Pain
No longer recruiting/follow-up only
12-120 Years
NCI
20-C-0127
A Phase 1 Study of Romidepsin, CC-486 (5-azacitidine), dexamethasone, and lenalidomide (RAdR) for relapsed/refractory T-cell malignancies
No longer recruiting/follow-up only
18-125 Years
NCI
20-C-0121
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel
Participants currently recruited/enrolled
18-120 Years
NCI
20-C-0107
Clinical, Genetic, and Epidemiologic Study of Children and Adults with RASopathies
Participants currently recruited/enrolled
0-125 Years
NCI
20-C-0106
Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients with BAP1 Tumor Predisposition Syndrome
Participants currently recruited/enrolled
30-125 Years
NCI
20-C-0104
Phase I/II Trial of HPV Vaccine PRGN-2009 Alone or in Combination with Anti-PD-L1/TGF-Beta Trap (M7824) in Subjects with HPV Positive Cancers
No longer recruiting/follow-up only
18-120 Years
NCI
20-C-0103
Investigation of the B- and T-cell Repertoire and Immune Response in Patients with Acute and Resolved COVID-19 Infection
No longer recruiting/follow-up only
18-125 Years
NCI
20-C-0097
A Phase II, Open-Label Trial of Bintrafusp Alfa (M7824) in Subjects with Thymoma and Thymic Carcinoma
Participants currently recruited/enrolled
18-125 Years
NCI
20-C-0076
Phase 2 Trial of Encorafenib plus Binimetinib for Patients with BRAF V600 Mutated Relapsed/Refractory HCL
Participants currently recruited/enrolled
18-125 Years
NCI
20-C-0075
Phase 2 Trial for Binimetinib for Patients with Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant
Participants currently recruited/enrolled
18-125 Years
NCI
20-C-0070
A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Patients with Inborn Errors of Immunity
Participants currently recruited/enrolled
4-69 Years
NCI
20-C-0069
A First-In-Human Phase I Single-Agent Dose-Escalation and Dose Expansion Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Participants currently recruited/enrolled
18-125 Years
NCI
20-C-0065
A Phase II Feasibility Trial Using Immersive Virtual Reality (VR) at the Time of Clinical Evaluation to Improve Psychological Distress and Anxiety in Primary Brain Tumor (PBT) Patients
Participants currently recruited/enrolled
18-125 Years
NCI
20-C-0062
A phase 1b Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)
Participants currently recruited/enrolled
18-125 Years
NCI
20-C-0061
Phase I/II study of NHS-IL12 Monotherapy and in Combination with M7824 in Advanced Kaposi Sarcoma
Participants currently recruited/enrolled
18-125 Years
NCI
20-C-0058
A Study of Front Line Ibrutinib without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease
Participants currently recruited/enrolled
18-125 Years
NCI
20-C-0051
Gene Therapy Follow up Protocol for Subjects Previously Enrolled in NCI Center for Immuno-Oncology Studies
Enrolling by Invitation
18-120 Years
NCI
20-C-0045
Phase I/II Trial of Combination Immunotherapy in Subjects with Advanced HPV Associated Malignancies
No longer recruiting/follow-up only
18-125 Years
NCI
20-C-0041
Protocol for a Research Database for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries
Enrolling by Invitation
1-125 Years
NCI
20-C-0028
Phase 1/2 Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults with Relapsed/Refractory Acute Myeloid Leukemia
Participants currently recruited/enrolled
3-35 Years
NCI
20-C-0027
A Phase I Clinical Trial of Selinexor (KPT-330) in Combination with Temozolomide and Radiation Therapy in Patients with Newly Diagnosed Glioblastoma
Participants currently recruited/enrolled
18-125 Years
NCI
20-C-0024
A Sequential Window of Opportunity Trial of Anti-PD-L1/TGF-beta trap (M7824 ) Alone and in Combination with TriAd Vaccine, and N-803 for Resectable Head and Neck Squamous Cell Carcinoma not Associated with Human Papillomavirus Infection.
Completed Study; data analyses ongoing
18-120 Years
NCI
20-C-0023
First-in-Human Phase I Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Metarrestin (ML-246) in Subjects with Metastatic Solid Tumors
Participants currently recruited/enrolled
12-120 Years
NCI
20-C-0022
Phase II trial of VB-111 in Combination with Nivolumab in Patients with Metastatic Colorectal Cancer (mCRC)
Completed Study; data analyses ongoing
18-125 Years
NCI
20-C-0020
Ex-Vivo Trial of En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device
Participants currently recruited/enrolled
18-125 Years
NCI
20-C-0013
Phase I/II Trial of PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers
No longer recruiting/follow-up only
18-125 Years
NCI
20-C-0012
A Phase I Study of Bintrafusp alfa (M7824) and NHS-IL12 (M9241) Alone and in Combination with Stereotactic Body Radiation Therapy (SBRT) in Adults with Metastatic Non-Prostate Genitourinary Malignancies
Participants currently recruited/enrolled
18-125 Years
NCI
20-C-0011
Phase 1 Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for Patients with Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome
Completed Study; data analyses ongoing
18-125 Years
NCI
20-C-0010
Phase II Trial of Radium-223 in Biochemically Recurrent Prostate Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
20-C-0009
Randomized Phase II Trial of Topotecan Plus M6620 (VX-970) vs. Topotecan Alone in Patients with Relapsed Small-Cell Lung Cancer
No longer recruiting/follow-up only
18-125 Years
NCI
20-C-0006
A National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer (PLC)
Participants currently recruited/enrolled
18-125 Years
NCI
19-C-0142
Identifying Predictors of Poor Health-Related Quality-of-Life Among Pediatric Hematopoietic Stem Cell Donors
Participants currently recruited/enrolled
5-125 Years
NCI
19-C-0138
Phase I/II Study of Lu-177-DOTATATE (Lutathera) in Combination with Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
Participants currently recruited/enrolled
18-125 Years
NCI
19-C-0137
A Phase II Study of Ipilimumab, Cabozantinib, and NIvolumab in Rare Genitourinary Cancers (ICONIC)
Participants currently recruited/enrolled
18-125 Years
NCI
19-C-0136
A Phase 2, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects with Chronic Graft Versus Host Disease (CGVHD) After at Least 2 Prior Lines of Systemic Therapy
Completed Study; data analyses ongoing
18-125 Years
NCI
19-C-0135
Evaluation of the Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
Participants currently recruited/enrolled
12-125 Years
NCI
19-C-0131
Development and Psychometric Testing of a Pediatric Chronic Graft- Versus-Host Disease (GVHD) Symptom Scale (PCSS)
Participants currently recruited/enrolled
5-125 Years
NCI
19-C-0129
A Phase II Study of Intraperitoneal and Intravenous Paclitaxel Chemotherapy with Oral Capecitabine for Gastric Adenocarcinoma with Peritoneal Carcinomatosis
No longer recruiting/follow-up only
18-125 Years
NCI
19-C-0128
A Phase I Study of Mesothelin-Targeted Immunotoxin LMB-100 in Combination with Tofacitinib in Persons with Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and other Mesothelin Expressing Solid Tumors
Completed Study; data analyses ongoing
18-125 Years
NCI
19-C-0123
DURVA PLUS: Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody Durvalumab in Combination with Chemotherapy in Patients with Advanced Solid Tumors
Participants currently recruited/enrolled
18-125 Years
NCI
19-C-0117
A Phase 1 / 2 Single Arm Open-label Clinical Trial of Gavocabtagene Autoleucel (gavo-cel) in Patients with Advanced Mesothelin Expressing Cancer
No longer recruiting/follow-up only
18-120 Years
NCI
19-C-0116
A Phase 2 Study of Acalabrutinib with DA-EPOCH-R or R-CHOP for Patients with Untreated Diffuse Large B-cell Lymphoma
Participants currently recruited/enrolled
18-125 Years
NCI
19-C-0112
Phase I/II Study De-intensifying Exposure of Post-transplantation Cyclophosphamide as GVHD Prophylaxis after HLA-haploidentical Hematopoietic Cell Transplantation for Hematologic Malignancies
Participants currently recruited/enrolled
12-120 Years
NCI
19-C-0104
A Phase II Multi-Institutional Trial to Evaluate Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
19-C-0103
A Study of Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas with Secondary Involvement of the Central Nervous System (CNS)
No longer recruiting/follow-up only
18-125 Years
NCI
19-C-0102
A Phase I Clinical Trial of T-cells Expressing an anti-SLAMF7 CAR for Treating Multiple Myeloma
Completed Study; data analyses ongoing
18-73 Years
NCI
19-C-0096
Studying the Biology of IDH-mutant Gliomas via Longitudinal Observation of 2-Hydroxyglutarate (2-HG) Using MR Spectroscopy
Participants currently recruited/enrolled
18-125 Years
NCI
19-C-0094
A Phase II Study of Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects with Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinoma (BTC)
Participants currently recruited/enrolled
18-125 Years
NCI
19-C-0085
Phase II Trial of Allogeneic Hematopoietic Cell Transplantation for Peripheral T cell Lymphoma
Participants currently recruited/enrolled
12-120 Years
NCI
19-C-0082
Natural History Study of Children and Adults with Chordoma
Participants currently recruited/enrolled
2-125 Years
NCI
19-C-0062
A Phase II Study of Neoadjuvant Androgen Deprivation Therapy Combined with Enzalutamide and Abiraterone Using Multiparametric MRI and 18F-DCFPyL-PET/CT in Newly Diagnosed Prostate Cancer
No longer recruiting/follow-up only
18-125 Years
NCI
19-C-0061
A Phase 2 Trial of the MEK Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Combination with the mTOR Inhibitor Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors
Completed Study; data analyses ongoing
12-125 Years
NCI
19-C-0049
Long Term Follow-up of Mesothelioma Patients and Their Family Members with Germline Mutations in BAP1 and Other Genes
Participants currently recruited/enrolled
2-125 Years
NCI
19-C-0046
Long-Term Follow-up Protocol for Subjects Treated with Gene-Modified T cells.
No longer recruiting/follow-up only
18-125 Years
NCI
19-C-0042
A Phase I Study of Moxetumomab Pasudotox-tdfk (Lumoxiti (TM)) and either Rituximab (Rituxan (R)) or Ruxience for Relapsed Hairy Cell Leukemia
No longer recruiting/follow-up only
18-125 Years
NCI
19-C-0041
Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)
Completed Study; data analyses ongoing
18-125 Years
NCI
19-C-0040
Natural History Study of Men at High Genetic Risk for Prostate Cancer
Participants currently recruited/enrolled
30-75 Years
NCI
19-C-0039
Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers
Completed Study; data analyses ongoing
18-125 Years
NCI
19-C-0033
Phase II Study of Nivolumab (anti-PD1), Tadalafil and Oral Vancomycin in Patients with Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer from Colorectal or Pancreatic Cancers
Completed Study; data analyses ongoing
18-125 Years
NCI
19-C-0030
A Phase 2 Study of Response-Adapted Therapy with Copanlisib and Rituximab in Untreated Follicular Lymphoma
No longer recruiting/follow-up only
18-125 Years
NCI
19-C-0025
Tissue Acquisition and Genomics Analysis of Breast Cancer and Other Gynecologic Malignancies
Enrolling by Invitation
18-125 Years
NCI
19-C-0023
A Phase II Study of Olaparib (AZD2281) in Patients with Metastatic/Advanced Urothelial Carcinoma and other genitourinary tumors with DNA-Repair Defects
Participants currently recruited/enrolled
18-125 Years
NCI
19-C-0017
A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced with a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients
Participants currently recruited/enrolled
18-72 Years
NCI
19-C-0016
Natural History and Biospecimen Acquisition Study for Children and Adults with Rare Solid Tumors
Participants currently recruited/enrolled
0-125 Years
NCI
19-C-0010
A Phase 1 Trial of MK-3475 Plus Ziv-Aflibercept in Patients with Advanced Solid Tumors
Completed Study; data analyses ongoing
18-125 Years
NCI
19-C-0006
Phase II Trial Evaluating Nivolumab In Patients With IDH-Mutant Gliomas With And Without Hypermutator Phenotype
Participants currently recruited/enrolled
18-125 Years
NCI
18-DC-0051
Biospecimen Procurement for the Study of Head and Neck Disorders
Participants currently recruited/enrolled
3-120 Years
NCI
18-C-0147
Phase 1 with Expansion Cohorts in a Study of NEO-201 In Adults with Chemo-Resistant Solid Tumors
Participants currently recruited/enrolled
18-125 Years
NCI
18-C-0143
A Phase 1 Study of Intraperitoneal MCY-M11 Therapy for Women with Platinum Resistant High Grade Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube, or Subjects with Peritoneal Mesothelioma with Recurrence after Prior Chemotherapy
Completed Study; data analyses ongoing
18-125 Years
NCI
18-C-0138
An Open-Label Phase 2 Study to Evaluate PT2977 for the Treatment of Von Hippel-Lindau Disease-Associated Renal Cell Carcinoma.
No longer recruiting/follow-up only
18-125 Years
NCI
18-C-0135
Phase II Trial of Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation
Participants currently recruited/enrolled
4-125 Years
NCI
18-C-0125
A Phase I Clinical Trial of T cells Expressing a Novel Fully-human Anti-BCMA CAR for Treating Multiple Myeloma
No longer recruiting/follow-up only
18-73 Years
NCI
18-C-0122
Phase 1B Study of Copanlisib in Combination with Nivolumab or with Nivolumab and Ipilimumab
Completed Study; data analyses ongoing
18-125 Years
NCI
18-C-0110
Safety Run-In and Phase II Trial of M7824 and Topotecan or Temozolomide in Relapsed Small Cell Cancers
Participants currently recruited/enrolled
18-99 Years
NCI
18-C-0102
Pilot Study of the MEK1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) for Adults with Neurofibromatosis Type 1 (NF1) and Cutaneous Neurofibromas (cNF)
Completed Study; data analyses ongoing
18-125 Years
NCI
18-C-0093
Pilot Study of Medication Adherence in Children, Adolescents, and Adults with Neurofibromatosis Type 1 (NF1) on Clinical Treatment Trials
Completed Study; data analyses ongoing
3-125 Years
NCI
18-C-0080
Feasibility and Preliminary Efficacy of an Enhanced Mindfulness Intervention for Children and Young Adults with High Grade or High-Risk Cancer and Their Caregivers: A Pilot Randomized Controlled Trial
Completed Study; data analyses ongoing
5-125 Years
NCI
18-C-0078
A Phase I/II Study of Immunotherapy Combination BN-Brachyury vaccine, M7824, N-803 and Epacadostat (QuEST1)
No longer recruiting/follow-up only
18-120 Years
NCI
18-C-0062
Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Completed Study; data analyses ongoing
2-30 Years
NCI
18-C-0059
Phase 1 Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults with Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
Participants currently recruited/enrolled
3-39 Years
NCI
18-C-0058
A Pilot Study to Evaluate the Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration in Men with Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females
Participants currently recruited/enrolled
18-125 Years
NCI
18-C-0056
Phase II Trial of M7824 in Subjects with HPV Associated Malignancies
No longer recruiting/follow-up only
18-120 Years
NCI
18-C-0049
A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in Patients with Metastatic Cancer
Participants currently recruited/enrolled
18-72 Years
NCI
18-C-0034
A Phase 2 Study of ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma
Completed Study; data analyses ongoing
18-125 Years
NCI
18-C-0033
Phase I Study of Recombinant Interleukin 15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in Subjects with Refractory Cancers
Participants currently recruited/enrolled
18-125 Years
NCI
18-C-0028
A Phase I Trial of Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy
No longer recruiting/follow-up only
18-125 Years
NCI
18-C-0024
A Single-Arm Phase II Study of Hepatic Artery Infusion Pump Chemotherapy with Floxuridine and Dexamethasone in Combination with Systemic Chemotherapy for Patients with Colorectal Cancer Metastatic to the Liver
Participants currently recruited/enrolled
18-125 Years
NCI
18-C-0017
Profiling of Radiological Factors in Treatment and Outcomes in Prostate Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
18-C-0014
Phase I Trial of 5-aza-4'-thio-2'-Deoxycytidine (Aza-TdC) in Patients with Advanced Solid Tumors
Participants currently recruited/enrolled
18-120 Years
NCI
18-C-0008
Phase III Randomized Adjuvant study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) versus Observation
No longer recruiting/follow-up only
18-125 Years
NCI
18-C-0005
Phase II Trial of Combination Immunotherapy in Biochemically Recurrent Prostate Cancer
No longer recruiting/follow-up only
18-125 Years
NCI
17-C-0174
Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease
Participants currently recruited/enrolled
18-125 Years
NCI
17-C-0158
A Feasibility Study of Mobile Sensor Technologies to Assess General Symptomology of Cancer Patients
Enrolling by Invitation
18-120 Years
NCI
17-C-0157
A Phase I Single-Arm Study of the Combination of Durvalumab (MEDI4736) and Vicineum (oportuzumab monatox, VB4-845) in Subjects with High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated with Bacillus Calmette-Gu(SqrRoot)(Copyright)rin (BCG)
Completed Study; data analyses ongoing
18-125 Years
NCI
17-C-0156
Longitudinal Sample Collection and Tracking for the Developmental Therapeutics Clinic, National Cancer Institute
Participants currently recruited/enrolled
18-125 Years
NCI
17-C-0153
Phase I Trial of Image Guided Focally Dose Escalated Prostate SBRT for Locally Recurrent Prostate Cancer after Prior Radiotherapy
No longer recruiting/follow-up only
18-125 Years
NCI
17-C-0140
Phase I/II Evaluation of Oral Decitabine/Tetrahydrouridine as Epigenetic Priming for Pembrolizumab Immune Checkpoint Blockade in Inoperable Locally Advanced or Metastatic Non-Small Cell Lung Cancers, Esophageal Carcinomas, or Pleural Mesotheliomas
Completed Study; data analyses ongoing
18-99 Years
NCI
17-C-0137
Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing
Enrolling by Invitation
3-65 Years
NCI
17-C-0127
Phase 1b/2 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Participants currently recruited/enrolled
18-125 Years
NCI
17-C-0125
Phase 2 Trial of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-Hodgkin Lymphomas
Participants currently recruited/enrolled
12-125 Years
NCI
17-C-0115
Phase I/II Study of T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery
Completed Study; data analyses ongoing
18-125 Years
NCI
17-C-0113
A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced with a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Participants currently recruited/enrolled
18-72 Years
NCI
17-C-0109
18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer
Enrolling by Invitation
18-125 Years
NCI
17-C-0105
Prospective Study of Clonal Evolution in Follicular Lymphoma
Participants currently recruited/enrolled
18-125 Years
NCI
17-C-0102
Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients with Recurrent Select Rare CNS Cancers
Participants currently recruited/enrolled
18-99 Years
NCI
17-C-0100
Collection of Malignant Ascites, Pleural Fluid and Blood from Patients with Solid Tumors
Completed Study; data analyses ongoing
18-125 Years
NCI
17-C-0092
A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination with Immune Checkpoint Inhibition in Refractory Colorectal Cancer
Completed Study; data analyses ongoing
18-125 Years
NCI
17-C-0089
Evaluation of 18F-DCFPyL PSMA- versus 18F-NaF-PET imaging for Detection of Metastatic Prostate Cancer
Enrolling by Invitation
18-125 Years
NCI
17-C-0087
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
Participants currently recruited/enrolled
18-125 Years
NCI
17-C-0086
An Open-label Phase 2 Study to Evaluate PT2385 for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma
No longer recruiting/follow-up only
18-125 Years
NCI
17-C-0074
A Phase 2 Study of Anti-PD-L1 Antibody Atezolizumab in Alveolar Soft Part Sarcoma
Participants currently recruited/enrolled
2-125 Years
NCI
17-C-0070
Phase II Trial of Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer with Positive Peritoneal Cytology
No longer recruiting/follow-up only
18-125 Years
NCI
17-C-0066
A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma after Progression on Platinum-Based Chemotherapy
Participants currently recruited/enrolled
18-125 Years
NCI
17-C-0061
Phase II Trial of Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer
Completed Study; data analyses ongoing
18-125 Years
NCI
17-C-0048
Anti-CD30 CAR T Cells with Fully-human Binding Domains for Treating CD30-expressing Lymphomas Including Anaplastic Large Cell Lymphomas
Completed Study; data analyses ongoing
18-73 Years
NCI
17-C-0045
A Phase I Study of Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas
Completed Study; data analyses ongoing
18-125 Years
NCI
17-C-0044
Prospective Evaluation and Molecular Profiling in Patients with Gastric Tumors
Participants currently recruited/enrolled
2-125 Years
NCI
17-C-0043
Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer
Participants currently recruited/enrolled
2-125 Years
NCI
17-C-0037
Phase II Trial of LB100, a Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma
Completed Study; data analyses ongoing
18-125 Years
NCI
17-C-0034
A Randomized, Double Blind Phase II Trial of Surgery, Radiation Therapy Plus Temozolomide and Pembrolizumab with and without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)
Completed Study; data analyses ongoing
18-125 Years
NCI
17-C-0028
A Pilot Study of Vincristine Sulfate Liposome Injection (Marqibo ) in Combination with Chemotherapy for Children, Adolescents, and Young Adults with Relapse of Acute Lymphoblastic Leukemia
Completed Study; data analyses ongoing
2-21 Years
NCI
17-C-0027
Long-Term Follow up of Patients Undergoing Hematopoietic Stem Cell Transplantation
Participants currently recruited/enrolled
4-125 Years
NCI
17-C-0011
Phase 1 Study of Intraperitoneal Infusion of Autologous Monocytes with Sylatron(R) (Peginterferon alfa-2b) and Actimmune(R) (Interferon gamma-1b) in Women with Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
Completed Study; data analyses ongoing
18-125 Years
NCI
17-C-0009
Phase I Trial of Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide (tmz) Followed by Randomized Phase II Trial of Zotiraciclib (TG02) plus Temozolomide versus Temozolomide alone in Adults with Recurrent Anaplastic Astrocytoma and Glioblastom
Completed Study; data analyses ongoing
18-125 Years
NCI
17-C-0007
Phase I/II Study of PROSTVAC in Combination with Nivolumab in Men with Prostate Cancer
Completed Study; data analyses ongoing
18-120 Years
NCI
16-C-0171
Phase I/II Study of Lenalidomide Combined with Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-Associated Large Cell Lymphoma
No longer recruiting/follow-up only
18-125 Years
NCI
16-C-0154
A Phase I/II Trial of T Cell Receptor Gene Therapy Targeting HPV-16 E7 for HPV-Associated Cancers
Participants currently recruited/enrolled
18-120 Years
NCI
16-C-0151
Evaluation of the Natural History of and Specimen Banking for Patients with Tumors of the Central Nervous System
No longer recruiting/follow-up only
18-125 Years
NCI
16-C-0138
Collection of Peripheral Blood Mononuclear Cells (PBMCs) from Healthy Subjects for the Expansion of T Cells for Adoptive Cell Therapy
Participants currently recruited/enrolled
18-120 Years
NCI
16-C-0135
A Pilot Study of Combined Immune Checkpoint Inhibition in combination with Ablative Therapies in Subjects with Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
Completed Study; data analyses ongoing
18-125 Years
NCI
16-C-0131
A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced with a CD70-Binding Chimeric Antigen Receptor to Patients with CD70-Expressing Cancers
Participants currently recruited/enrolled
18-72 Years
NCI
16-C-0128
A Phase I/II Study of Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination with Nab-Paclitaxel in Participants with Previously Treated Metastatic and/ or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors
Completed Study; data analyses ongoing
18-125 Years
NCI
16-C-0121
A Pilot Clinical Trial of Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma
Completed Study; data analyses ongoing
18-125 Years
NCI
16-C-0107
A Phase I/II Trial of EP0057, a Nanoparticle Camptothecin with Olaparib in Patients with Relapsed/Refractory Small Cell Lung, Bladder and Prostate Cancers
Participants currently recruited/enrolled
18-125 Years
NCI
16-C-0097
Phase 1 Trial of Panobinostat in Children with Diffuse Intrinsic Pontine Glioma
Completed Study; data analyses ongoing
2-21 Years
NCI
16-C-0094
A Phase 1/2 Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease (cGVHD) after Allogeneic Hematopoietic Stem Cell Transplantation (SCT)
No longer recruiting/follow-up only
18-125 Years
NCI
16-C-0092
A Pilot Study of Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-mutated, Non-Small Cell Lung Cancer (NSCLC) After Treatment with Osimertinib (AZD9291, Tagrisso)
Completed Study; data analyses ongoing
18-125 Years
NCI
16-C-0088
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritonea
Completed Study; data analyses ongoing
18-125 Years
NCI
16-C-0087
Phase I Study of Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor in Combination with Cisplatin in Patients with Refractory Solid Tumors
Completed Study; data analyses ongoing
18-125 Years
NCI
16-C-0081
A Phase I Dose Escalation Trial of Re-Irradiation in Good Prognosis Recurrent Glioblastoma
Completed Study; data analyses ongoing
18-125 Years
NCI
16-C-0076
Prospective Screening for Patient Specific Genotypes and Phenotypes that Influence Drug Dosing and Trial Selection in Cancer Patients
Enrolling by Invitation
18-125 Years
NCI
16-C-0073
A Phase 2 Study of Olaparib and Cediranib for the Treatment of Recurrent Ovarian Cancer
Completed Study; data analyses ongoing
18-125 Years
NCI
16-C-0066
Phase I Study of MK-3475 (Pembrolizumab) in Patients with Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant Neoplasm
Completed Study; data analyses ongoing
18-120 Years
NCI
16-C-0061
Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
Participants currently recruited/enrolled
18-120 Years
NCI
16-C-0060
A Phase 1b/2 Study of alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation
Participants currently recruited/enrolled
18-125 Years
NCI
16-C-0048
Docetaxel and Prostvac for Metastatic Castration Sensitive Prostate Cancer
No longer recruiting/follow-up only
18-125 Years
NCI
16-C-0047
A Phase 1 Trial of Pomalidomide in Combination with Liposomal Doxorubicin in Patients with Advanced or Refractory Kaposi Sarcoma
No longer recruiting/follow-up only
18-125 Years
NCI
16-C-0043
Phase II Trial of the MEK1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate in Adults with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
No longer recruiting/follow-up only
18-125 Years
NCI
16-C-0035
Prostvac in Patients with Biochemically Recurrent Prostate Cancer
Completed Study; data analyses ongoing
18-125 Years
NCI
16-C-0034
A Phase II Trial of Oral Pazopanib plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) without Prior Bevacizumab Exposure and (B) after Failing Prior Bevacizumab
Completed Study; data analyses ongoing
18-125 Years
NCI
16-C-0027
A Prospective Randomized and Phase II Trial for Metastatic Melanoma Using Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
Clinical hold/Recruitment or enrollment suspended
18-70 Years
NCI
16-C-0011
A Phase I-II Trial of Everolimus and Sorafenib in Patients with Recurrent High-Grade Gliomas
Completed Study; data analyses ongoing
18-125 Years
NCI
16-C-0010
Care of the Prostate Cancer Patient and Prospective Procurement of Prostate Cancer Tissue
Participants currently recruited/enrolled
18-125 Years
NCI
16-C-0009
Phase II Trial of Carboplatin and Bevacizumab for the Treatment of Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma in Adults: A Multi-Center Trial
Completed Study; data analyses ongoing
18-125 Years
NCI
16-C-0003
Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
Participants currently recruited/enrolled
4-75 Years
NCI
15-C-0200
Molecular Analysis for Therapy Choice (MATCH) (EAY131)
Completed Study; data analyses ongoing
18-125 Years
NCI
15-C-0195
Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals with Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs)
Participants currently recruited/enrolled
5-125 Years
NCI
15-C-0160
A Phase I Study of Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination with Ipilimumab (CaboNivoIpi) in Patients with Advanced/Metastatic Urothelial Carcinoma and other Genitourinary Tumors
No longer recruiting/follow-up only
18-125 Years
NCI
15-C-0157
Phase I/II Trial of Vandetanib in Combination with Metformin in Subjects with HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma
Completed Study; data analyses ongoing
18-125 Years
NCI
15-C-0150
A Phase I/II Trial of Topotecan with VX-970 (M6620), an ATR Kinase Inhibitor in Small Cell Cancers
No longer recruiting/follow-up only
18-125 Years
NCI
15-C-0145
Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody Durvalumab (MEDI4736) in Combination with Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers
Participants currently recruited/enrolled
18-125 Years
NCI
15-C-0142
Acceptance and Commitment Training for Adolescents and Adults with Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain: A Phase III Clinical Trial
Completed Study; data analyses ongoing
16-59 Years
NCI
15-C-0141
Gene Therapy Follow up Protocol for Subjects Previously Enrolled in CAR T-Cell Studies
Enrolling by Invitation
18-125 Years
NCI
15-C-0124
Neoadjuvant Androgen Deprivation and Enzalutamide: Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer
No longer recruiting/follow-up only
18-125 Years
NCI
15-C-0116
Phase I Trial of 4'-thio-2'-deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors
Clinical hold/Recruitment or enrollment suspended
18-125 Years
NCI
15-C-0099
A Phase 1, Open-Label, Dose-Escalation Study of SNX-5422 and Everolimus in Subjects with Neuroendocrine Tumors
Completed Study; data analyses ongoing
18-100 Years
NCI
15-C-0093
Phase I Trial of TURALIO (pexidartinib, PLX3397) in Children and Young Adults with Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor (TGCT
Participants currently recruited/enrolled
3-35 Years
NCI
15-C-0087
Care of the Urothelial Cancer Patient and Prospective Collection of Biospecimens from Healthy Volunteers and Urothelial Cancer Patients
Participants currently recruited/enrolled
18-125 Years
NCI
15-C-0086
Phase I Trial of the Combination of Nilotinib and Paclitaxel in Adults and Pediatric Patients with Refractory Solid Tumors
Participants currently recruited/enrolled
12-120 Years
NCI
15-C-0078
Safety and Feasibility of Stem Cell Gene Transfer Following R-EPOCH for Non-Hodgkin Lymphoma in AIDS Patients Using Peripheral Blood Stem/Progenitor Cells Treated with a Lentivirus Vector-Encoding Multiple Anti-HIV RNAs
No longer recruiting/follow-up only
18-65 Years
NCI
15-C-0076
A Pilot Study of Long Term TARP Vaccination Using A Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Previously Vaccinated Men on NCI 09-C-0139
Completed Study; data analyses ongoing
18-125 Years
NCI
15-C-0075
A Randomized, Placebo-Controlled Phase II Study of Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Men with Stage D0 Prostate Cancer
Completed Study; data analyses ongoing
18-125 Years
NCI
15-C-0067
A Phase I/II Open Label, Dose Escalation Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
Participants currently recruited/enrolled
18-125 Years
NCI
15-C-0029
Phase I Dose Escalation Study of Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults with Recurrent or Refractory CD22-expressing B Cell Malignancies
No longer recruiting/follow-up only
3-39 Years
NCI
15-C-0028
Follow-Up Evaluation for Gene-Therapy Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials
Enrolling by Invitation
1-99 Years
NCI
15-C-0019
The Impact of Ras/MAPK Signaling Pathway-Targeted Therapies on Neurocognitive Functioning in Individuals with NF1
Completed Study; data analyses ongoing
4-99 Years
NCI
14-C-0163
Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1: Clinical, Histopathologic, and Genomic Analysis
Completed Study; data analyses ongoing
10-125 Years
NCI
14-C-0161
Phase I Trial of the Combination of Bortezomib and Clofarabine in Adults with Refractory Solid Tumors, Lymphomas, or Myelodysplastic Syndromes
Participants currently recruited/enrolled
18-120 Years
NCI
14-C-0157
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, Rituximab (TEDDI-R) in Primary CNS Lymphoma
Participants currently recruited/enrolled
18-125 Years
NCI
14-C-0156
A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) In BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, and High Grade Serous Ovarian Cancer
Completed Study; data analyses ongoing
18-125 Years
NCI
14-C-0128
Collection of Pharmacokinetic and Probe Substrate Samples from Participants with Unanticipated Response, Significant Toxicity or Concern of Future Toxicity
Enrolling by Invitation
2-125 Years
NCI
14-C-0116
A Randomized Controlled Trial Evaluating an Enhanced Physical Activity Intervention to Improve Cognitive Late Effects in Children Treated with Cranial Radiation for Brain Tumors
Participants currently recruited/enrolled
8-125 Years
NCI
14-C-0105
Tissue Procurement and Natural History Study of Patients with Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors
Participants currently recruited/enrolled
18-125 Years
NCI
14-C-0104
A Phase II Study Using Autologous Young Tumor-Infiltrating Lymphocytes Derived from Patients with Non-Small Cell Lung Cancer Following Non-Myeloablative Lymphocyte Depleting Preparative Regimen
Participants currently recruited/enrolled
18-72 Years
NCI
14-C-0079
An Exploratory Study of Voicing My CHOiCES as a Tool for Advanced Care Planning in Young Adults with Cancer and Other Chronic Illnesses
Participants currently recruited/enrolled
18-125 Years
NCI
14-C-0059
A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults with GD2+ Solid Tumors
Completed Study; data analyses ongoing
1-35 Years
NCI
14-C-0037
A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer
Completed Study; data analyses ongoing
18-125 Years
NCI
14-C-0036
A Randomized, Prospective, Phase II Study to Determine the Efficacy of Bacillus Calmette-Guerin (BCG) Given in Combination with PANVAC[TM] Versus BCG Given Alone in Adults with High Grade Non-Muscle Invasive Bladder Cancer (NMIBC) Who Failed at Least 1 I
Completed Study; data analyses ongoing
18-125 Years
NCI
14-C-0022
A Phase II Study for Metastatic Melanoma Using High-Dose Chemotherapy Preparative Regimen Followed by Cell Transfer Therapy Using Tumor-Infiltrating Lymphocytes Plus IL-2 with the Administration of Pembrolizumab in the Retreatment Arm
Completed Study; data analyses ongoing
18-70 Years
NCI
14-C-0004
A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) for Treatment of Relapsed Hairy Cell Leukemia
No longer recruiting/follow-up only
18-125 Years
NCI
14-C-0001
Phase II Study of Axitinib (AG-013736) with Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma
Completed Study; data analyses ongoing
18-125 Years
NCI
13-C-0202
Tissue Procurement and Natural History Study of Patients with Malignant Mesothelioma and Other Mesothelin Expressing Cancers
Participants currently recruited/enrolled
2-125 Years
NCI
13-C-0176
Tumor, Normal Tissue and Specimens from Patients Undergoing Evaluation or Surgical Resection of Solid Tumors
Participants currently recruited/enrolled
2-125 Years
NCI
13-C-0153
A Phase II Trial of Enzalutamide in Combination with PSA-TRICOM in Patients with Non-Metastatic Castration Sensitive Prostate Cancer
Completed Study; data analyses ongoing
18-125 Years
NCI
13-C-0152
A Phase I Study of Autologous Activated Natural Killer (NK) Cells +/- rhIL15 in Children and Young Adults with Refractory Solid Tumors
Completed Study; data analyses ongoing
2-29 Years
NCI
13-C-0146
A Randomized Phase II Trial Combining Vaccine Therapy with PROSTVAC /TRICOM and Enzalutamide vs. Enzalutamide Alone in Men with Metastatic Castration Resistant Prostate Cancer
Completed Study; data analyses ongoing
18-125 Years
NCI
13-C-0132
Allogeneic Hematopoietic Stem Cell Transplant for Patients with Mutations in GATA2 or the MonoMAC Syndrome
Participants currently recruited/enrolled
8-70 Years
NCI
13-C-0131
Inpatient Hospice with Procurement of Tissue on Expiration in Thoracic Malignancies, Bladder Cancer, Ovarian Cancer, Epithelial Cancer and Patients Treated with an Adoptive Cellular Therapy
Participants currently recruited/enrolled
18-120 Years
NCI
13-C-0119
Evaluation of Local Response of Prostate Cancer to Irradiation Using Multiparametric MRI and MR-Guided Biopsies
Participants currently recruited/enrolled
18-125 Years
NCI
13-C-0118
A Phase I/II Trial of TRC102 (methoxyamine HCl) in Combination with Temozolomide in Patients with Relapsed Solid Tumors and Lymphomas
Completed Study; data analyses ongoing
18-120 Years
NCI
13-C-0105
Molecular Profiling-based Assignment of Cancer Therapy for Patients With Advanced Solid Tumors
Completed Study; data analyses ongoing
18-120 Years
NCI
13-C-0095
A Phase 2 Study of GI-6207 in Patients with Recurrent Medullary Thyroid Cancer
Completed Study; data analyses ongoing
18-125 Years
NCI
12-C-0206
Understanding the Perceived Influence of Childhood Cancer and NF1 on the Parents' Marital/Partner Relationship: A Descriptive Study
Completed Study; data analyses ongoing
18-125 Years
NCI
12-C-0205
A Phase II Study of Cabozantinib (XL184) in Patients With Advanced/Metastatic Urothelial Carcinoma
Completed Study; data analyses ongoing
18-125 Years
NCI
12-C-0197
A Randomized Phase 2 Single-Center Study of Pomalidomide for Chronic GvHD
Completed Study; data analyses ongoing
18-75 Years
NCI
12-C-0193
Lymphoid Malignancies and Precursors: Tissue Acquisition Protocol
Participants currently recruited/enrolled
18-125 Years
NCI
12-C-0178
Longitudinal Assessment and Natural History Study of Children and Adults with MEN2A or MEN2B with or without Medullary Thyroid Carcinoma
Participants currently recruited/enrolled
0-125 Years
NCI
12-C-0160
Validation of the English Version of the Pain Interference Index and the Pain Rating Scale in Children, Adolescents, and Adults with Chronic Illness and their Parents
Completed Study; data analyses ongoing
18-125 Years
NCI
12-C-0118
A Phase II Study of Sunitinib in Patients with Advanced Relapsed or Refractory Thymoma or Thymic Carcinoma with at Least One Prior Line of Platinum-Based Systemic Chemotherapy
No longer recruiting/follow-up only
18-100 Years
NCI
12-C-0107
Carfilzomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma: a Clinical and Correlative Pilot Study
No longer recruiting/follow-up only
18-125 Years
NCI
12-C-0081
Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer
No longer recruiting/follow-up only
18-125 Years
NCI
12-C-0079
A Phase II Multicenter Study of AMG 386 and Abiraterone in Metastatic Castration Resistant Prostate Cancer
Completed Study; data analyses ongoing
18-125 Years
NCI
12-C-0068
A Randomized Double-Blind Pilot Study of Topical Clobetasol 0.05% Oral rinse for Oral Chronic Graft-Versus-Host Disease
Completed Study; data analyses ongoing
12-125 Years
NCI
12-C-0066
Phase I Trial of Oral 5-Fluoro-2'-Deoxycytidine with Oral Tetrahydrouridine in Patients with Advanced Solid Tumors
Completed Study; data analyses ongoing
18-125 Years
NCI
11-C-0255
Clinical, Epidemiologic, and Genetic Studies of Li-Fraumeni Syndrome
Participants currently recruited/enrolled
0-125 Years
NCI
11-C-0247
A Randomized Phase II Study of Tecemotide in Combination with Standard Androgen Deprivation Therapy and Radiation Therapy for untreated, intermediate and High Risk Prostate Cancer Patients
Completed Study; data analyses ongoing
18-100 Years
NCI
11-C-0242
Collection of Blood from Patients with Cancer, Other Tumors, or Tumor Predisposition Syndromes for Analysis of Genetic Differences in Drug Disposition
Participants currently recruited/enrolled
3-125 Years
NCI
11-C-0220
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
Participants currently recruited/enrolled
18-125 Years
NCI
11-C-0200
A Phase II Trial In Which Patients With Metastatic Alveolar Soft Part Sarcoma Are Randomized to Either Sunitinib or Cediranib Monotherapy, with Cross-Over at Disease Progression
No longer recruiting/follow-up only
16-120 Years
NCI
11-C-0190
Collection of Tissue Blocks or Slides from Patients with Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
11-C-0161
A Phase I/II Study of the Mitogen Activated Protein Kinase Kinase (MEK) 1 Inhibitor Selumetinib (AZD6244; Hydrogen Sulfate in Children with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)
No longer recruiting/follow-up only
2-18 Years
NCI
11-C-0140
A Phase I Study of Gemcitabine, Carboplatin and Lenalidomide (GCL) for Treatment of Patients with Advanced/Metastatic Urothelial Carcinoma (UC) and Other Solid Tumors
Completed Study; data analyses ongoing
18-125 Years
NCI
11-C-0136
Multi-Institutional Prospective Pilot Study of Lupron to Enhance Lymphocyte Immune Reconstitution Following Allogeneic Bone Marrow Transplantation in Post-Pubertal Children and Adults with Molecular Imaging Evaluation
Completed Study; data analyses ongoing
2-120 Years
NCI
11-C-0132
Understanding the Psychosocial Needs of Parents Who Have Lost a Child to Cancer
Completed Study; data analyses ongoing
18-99 Years
NCI
11-C-0123
A Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Short-Term Cultured Tumor-Infiltrating Lymphocytes Plus IL-2 Following Either a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Alone or in Conjunction with
No longer recruiting/follow-up only
18-66 Years
NCI
11-C-0112
Acquisition of Blood and Tumor Tissue Samples from Patients with Gastrointestinal Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
11-C-0096
Pilot Trial of Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
No longer recruiting/follow-up only
18-125 Years
NCI
11-C-0061
Phase I Trial of Z-Endoxifen in Adults with Refractory Hormone Receptor-Positive Breast Cancer, Desmoid Tumors, Gynecologic Tumors, or other Hormone Receptor-Positive Solid Tumors
No longer recruiting/follow-up only
18-125 Years
NCI
11-C-0034
DICER1-Related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study
Participants currently recruited/enrolled
0-125 Years
NCI
11-C-0033
Extended Follow-up of High Ovarian Cancer Risk Cohort from 02C0268 (GOG-199)
Completed Study; data analyses ongoing
18-100 Years
NCI
10-C-0201
Apheresis and CD34+ Selection of Mobilized Peripheral Blood CD34+ Cells from Patients with DOCK8 Deficiency, LAD-1, and GATA2 Deficiency
Participants currently recruited/enrolled
18-40 Years
NCI
10-C-0174
Related and Unrelated Donor Hematopoietic Stem Cell Transplant for DOCK8 Deficiency
Participants currently recruited/enrolled
4-120 Years
NCI
10-C-0166
A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphodepleting Regimen in Metastatic Cancers Plus the Administration of Pembrolizumab
Participants currently recruited/enrolled
18-72 Years
NCI
10-C-0114
A Phase II Study of Bevacizumab and Erlotinib in Subjects with Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer
Completed Study; data analyses ongoing
18-125 Years
NCI
10-C-0086
Comprehensive Omics Analysis of Pediatric Solid Tumors and Establishment of a Repository for Related Biological Studies
Participants currently recruited/enrolled
0-125 Years
NCI
10-C-0066
A Study of Hairy Cell and other Leukemias with a Focus on Recombinant Immunotoxins for Cancer Treatment
Participants currently recruited/enrolled
18-125 Years
NCI
10-C-0056
A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults With Relapsed Solid Tumors and Lymphomas
Completed Study; data analyses ongoing
18-125 Years
NCI
10-C-0054
Administration of Anti-CD19-Chimeric-Antigen-Receptor-Transduced T Cells from the Original Transplant Donor to Patients with Recurrent or Persistent B-Cell Malignancies After Allogeneic Stem Cell Transplantation
Completed Study; data analyses ongoing
18-75 Years
NCI
10-C-0025
Randomized Phase II Trial of Rituximab with Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia
No longer recruiting/follow-up only
18-125 Years
NCI
10-C-0011
Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas
Completed Study; data analyses ongoing
18-125 Years
NCI
09-C-0242
Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms
Participants currently recruited/enrolled
4-125 Years
NCI
09-C-0192
Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma
No longer recruiting/follow-up only
0-125 Years
NCI
09-C-0161
Follow-Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch Studies
Enrolling by Invitation
18-125 Years
NCI
09-C-0139
A Pilot Study of Vaccination with Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer
Completed Study; data analyses ongoing
18-125 Years
NCI
09-C-0120
An Exploratory Evaluation of Biomarkers in Blister Fluid in Healthy Volunteers and Irradiated Skin
Completed Study; data analyses ongoing
18-125 Years
NCI
09-C-0100
A Pilot Study of High Dose Rate Brachytherapy in The Radiation Oncology Branch
Participants currently recruited/enrolled
18-125 Years
NCI
09-C-0053
Autologous and Related/Unrelated Allogeneic Hematopoietic Stem Cell Transplant and Cellular Therapies Data Submission and Research Sample Collection to the Center for International Blood and Marrow Transplant Research (CIBMTR) and the National Marrow Don
Enrolling by Invitation
1-125 Years
NCI
09-C-0024
A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents and Young Adults
Completed Study; data analyses ongoing
12-26 Years
NCI
09-C-0019
A Phase I Study of Dasatinib in Combination with Bevacizumab in Advanced Solid Tumors
Completed Study; data analyses ongoing
18-125 Years
NCI
09-C-0005
Randomized Trial of Cladribine (CdA) with Simultaneous or Delayed Rituximab to Eliminate Hairy Cell Leukemia Minimal Residual Disease
No longer recruiting/follow-up only
18-125 Years
NCI
08-C-0214
A Pilot Study to Evaluate Neuropsychological Outcome Measures and their Relationship with Prognosis in Patients Receiving Radiation Therapy for Brain Metastases
Completed Study; data analyses ongoing
18-125 Years
NCI
08-C-0130
A Phase II Trial of Peginterferon alfa-2b (PEG-Intron) for Neurofibromatosis Type 1 Related Unresectable, Symptomatic or Life-Threatening Plexiform Neurofibromas
Completed Study; data analyses ongoing
0-21 Years
NCI
08-C-0079
Natural History Study and Longitudinal Assessment of Children, Adolescents, and Adults with Neurofibromatosis Type 1
No longer recruiting/follow-up only
0-125 Years
NCI
08-C-0020
A Phase II Study of ZD6474 (Vandetanib) in Patients with Von Hippel Lindau Disease and Renal Tumors
Completed Study; data analyses ongoing
18-120 Years
NCI
07-C-0195
Phase II Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation Using 8/8 and 7/8 HLA-matched Unrelated Donors and Utilizing Two Graft-versus-Host Disease Prophylaxis Regimens for the Trea
Completed Study; data analyses ongoing
18-74 Years
NCI
07-C-0121
Phase 2 Study of the C-Met RTK Inhibitor Foretinib (Formerly GSK 1363089) in Subjects with Papillary Renal Cell Carcinoma (PRC)
Completed Study; data analyses ongoing
18-125 Years
NCI
07-C-0110
Analysis of Stored Data Collected from Individuals Administered Neurobehavioral Assessments on IRB-Approved Protocols
Enrolling by Invitation
0-125 Years
NCI
07-C-0100
Collection of Blood from Patients with Prostate Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
06-C-0219
An Exploratory Study of Biologic and Pathophysiologic Effects of Radiation Therapy in Pediatric Patients with Central Nervous System Tumors
Completed Study; data analyses ongoing
0-21 Years
NCI
06-C-0213
Tissue Procurement Protocol for the Developmental Therapeutics Clinic, National Cancer Institute (NCI)
Participants currently recruited/enrolled
0-125 Years
NCI
06-C-0134
Natural History and Biology of Dermal Neurofibromas in Neurofibromatosis Type 1
Completed Study; data analyses ongoing
20-99 Years
NCI
06-C-0014
Prospective Evaluation of Genetic and Epigenetic Alterations in Patients with Thoracic Malignancies
Participants currently recruited/enrolled
2-125 Years
NCI
05-C-0252
Phase III Randomized Study of R-CHOP v. Dose-Adjusted EPOCH-R with Molecular Profiling in Untreated de Novo Diffuse Large B-Cell Lymphomas
Completed Study; data analyses ongoing
18-125 Years
NCI
05-C-0152
Variation in Gene Expression in Neurofibromatosis Type 1
Completed Study; data analyses ongoing
2-100 Years
NCI
04-C-0281
Natural History Study of Clinical and Biological Factors Determining Outcomes in Chronic Graft-Versus-Host Disease
Participants currently recruited/enrolled
1-125 Years
NCI
04-C-0275
Targeted Oncolytic Virotherapy and Natural History Study of KSHV-Associated Multicentric Castleman's Disease with Laboratory and Clinical Correlates of Disease Activity
No longer recruiting/follow-up only
18-125 Years
NCI
04-C-0274
Follow-Up Study of Subjects Previously Enrolled in Immunotherapy Studies Utilizing Gene Transfer or Other Immunotherapeutic Agents
Participants currently recruited/enrolled
18-125 Years
NCI
04-C-0238
A Phase 2 Study of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Von Hippel Lindau Disease and Renal Tumors
Completed Study; data analyses ongoing
18-125 Years
NCI
04-C-0232
A Multi-Institutional Study of Proteomic Evaluation of Epithelial Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer Patients in First Clinical Remission: Development of a Protein Fingerprint Profile of Relapse
Completed Study; data analyses ongoing
18-125 Years
NCI
04-C-0200
Urinary and Serum VEGF and MMP Levels in Patients Receiving Radiation Therapy for Glioblastoma Multiforme: Prospective Determination of a Predictive Value for Recurrence
Participants currently recruited/enrolled
18-125 Years
NCI
04-C-0165
Data Collection, Clinical Care and Interventions in CCR, NCI
Enrolling by Invitation
0-120 Years
NCI
04-C-0102
Hematologic Malignancy Biology Study
Enrolling by Invitation
1-75 Years
NCI
03-C-0277
Cell Harvest and Preparation for Surgery Branch Treatment Protocols
Enrolling by Invitation
18-125 Years
NCI
03-C-0066
Hereditary Leiomyomatosis Renal Cell Cancer (HLRCC): Identification of the Disease Gene, and Characterization of the Predisposition to Renal Cancer
Participants currently recruited/enrolled
2-125 Years
NCI
02-C-0268
Prospective Study of Prophylactic Salpingo-Oophorectomy and Longitudinal CA-125 Screening Among Women at Increased Genetic Risk of Ovarian Cancer
Completed Study; data analyses ongoing
19-100 Years
NCI
02-C-0212
Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer
Completed Study; data analyses ongoing
18-100 Years
NCI
02-C-0211
Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma
Participants currently recruited/enrolled
0-125 Years
NCI
02-C-0210
Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Blood and Lymph Node Malignancy
No longer recruiting/follow-up only
0-125 Years
NCI
02-C-0179
Biospecimen Acquisition from Human Subjects
Participants currently recruited/enrolled
18-125 Years
NCI
02-C-0178
Multidisciplinary Etiologic Study of Familial Testicular Cancer
No longer recruiting/follow-up only
12-125 Years
NCI
02-C-0159
Birt-Hogg-Dub(SqrRoot)(Copyright) Syndrome: Characterization of the FLCN Disease Gene and Predisposition to Renal Cancer, Cutaneous Fibrofolliculoma and Pulmonary Cysts
Participants currently recruited/enrolled
2-125 Years
NCI
02-C-0064
Collection of Peripheral Blood and/or Urine From Patients Undergoing Radiation Therapy
Enrolling by Invitation
18-125 Years
NCI
02-C-0052
Etiologic Investigation of Cancer Susceptibility in Inherited Bone Marrow Failure Syndromes: A Natural History Study
Participants currently recruited/enrolled
0-125 Years
NCI
01-C-0129
Eligibility Screening for the NIH Intramural Research Program Clinical Protocols
Enrolling by Invitation
0-125 Years
NCI
01-C-0038
Collection of Blood, Bone Marrow, Tumor, or Tissue Samples from Patients with HIV Infection, KSHV Infection, Viral-Related Pre-Malignant Lesions, and/or Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
01-C-0030
Short-Course EPOCH - Rituximab in Untreated CD-20+ HIV-Associated Lymphomas
Completed Study; data analyses ongoing
18-125 Years
NCI
01-C-0009
Breast Imaging Screening Studies in Women at High Genetic Risk of Breast Cancer: Annual Follow-up Study
Completed Study; data analyses ongoing
18-100 Years
NCI
00-C-0078
Collection of Blood, Fluid, Bone Marrow, Tumor, or Tissue Samples from Patients with Cancer or Normal Volunteers
Participants currently recruited/enrolled
18-125 Years
NCI
00-C-0074
Evaluation of Late Effects and Natural History of Disease in Patients Treated with Radiotherapy
Participants currently recruited/enrolled
18-125 Years
NCI
99-C-0128
Evaluation for NCI Surgery Branch Clinical Research Protocols
Participants currently recruited/enrolled
18-125 Years
NCI
99-C-0099
Examination of Clinical and Laboratory Abnormalities in Patients with Defective DNA Repair: Xeroderma Pigmentosum, Cockayne Syndrome, or Trichothiodystrophy
No longer recruiting/follow-up only
0-125 Years
NCI
97-C-0147
Collection of Serum and Tissue Samples from Patients with Biopsy-Proved or Suspected Malignant Diseases
Participants currently recruited/enrolled
2-125 Years
NCI
94-C-0074
Treatment and Natural History Study of Lymphomatoid Granulomatosis
No longer recruiting/follow-up only
12-125 Years
NCI
93-C-0133
Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Adults and Children with Previously Untreated Patients with Aggressive Non-Hodgkin's Lymphoma
No longer recruiting/follow-up only
12-125 Years
NCI
89-C-0086
Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders
Participants currently recruited/enrolled
2-125 Years
NCI
83-C-0022
Psychological Benefits of a Normalized Camping Experience for Children with Cancer
Participants currently recruited/enrolled
7-25 Years
NCI
78-C-0039
Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Cancer
No longer recruiting/follow-up only
0-125 Years
NCI